Review ArticlesPrognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysisGeng, Lia; Zong, Ruilongb; Shi, Yibingb; Xu, KaiaAuthor Information aDepartment of Radiology, The Affiliated Hospital of Xuzhou Medical University bDepartment of Radiology, Xuzhou Central Hospital, Xuzhou, China Received 18 September 2019 Accepted 25 October 2019 Corresponding author: Ruilong Zong, MD, Department of Radiology, Xuzhou Central Hospital, Xuzhou, China, Tel: +17712988956; fax: +0516 85790126; e-mail address: email@example.com European Journal of Gastroenterology & Hepatology: July 2020 - Volume 32 - Issue 7 - p 769-778 doi: 10.1097/MEG.0000000000001618 Buy Metrics Abstract Recent studies have reported albumin-bilirubin (ALBI) grade affected the prognosis of patients with hepatocellular carcinoma (HCC). To more precisely evaluate the relationship among the ALBI grade and the prognosis of patients with HCC after liver resection. We systematically retrieved articles from PubMed, Web of Science, Cochrane Library, and CNKI. The prognostic value of ALBI grade on overall survival (OS) and recurrence-free survival (RFS) of patients with HCC after liver resection was evaluated by pooled hazard ratio (HR) with 95% confidence interval (CI).Through multiple databases search, we enrolled 20 high-quality studies with 11365 patients, regarding the association between the ALBI grade and the prognosis of patients with HCC after liver resection. Our results showed that higher ALBI grade is associated with poored OS (HR, 1.64; 95% CI: 1.51–1.78; P < 0.001; I2 = 24.9%) and RFS (HR, 1.42; 95% CI: 1.26–1.59; P < 0.001; I2 = 0). Moreover, subgroup analysis showed the significant correlation between ALBI grade and poor long-term survival was not altered in different geographical areas, sample sizes, follow-up duration, and quality scores. The ALBI grade may be as effective predictive biomarkers for prognosis in patients with HCC after liver resection. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.